|

MK-2010 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC1

Indications

  • Ovarian Cancer Recurrent1
  • Cancer1

New Haven, Connecticut1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.